logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10206931 B1

PDFFull Text
Date of Patent:
Feb. 19, 2019

Filed:

Apr. 07, 2017

Therapeutic compounds and uses thereof

Applicants:

Genentech, Inc., South San Francisco, CA (US);

Constellation Pharmaceuticals, Inc., Cambridge, MA (US);

Inventors:

F. Anthony Romero, South San Francisco, CA (US);

Steven R. Magnuson, South San Francisco, CA (US);

Richard Pastor, South San Francisco, CA (US);

Vickie Hsiao-Wei Tsui, South San Francisco, CA (US);

Jeremy Murray, South San Francisco, CA (US);

Terry Crawford, South San Francisco, CA (US);

Daniel J. Burdick, South San Francisco, CA (US);

Brian K. Albrecht, Cambridge, MA (US);

Alexandre Cote, Cambridge, MA (US);

Alexander M. Taylor, Cambridge, MA (US);

Christopher G. Nasveschuck, Stoneham, MA (US);

Yves LeBlanc, Kirkland, CA;

Michael Charles Hewitt, Brookline, MA (US);

Kwong Wah Lai, Shanghai, CN;

Kevin Chen, Shanghai, CN;

Assignees:

GENENTECH, INC., South San Francisco, CA (US);

CONSTELLATION PHARMACEUTICALS, INC., Cambridge, MA (US);

Attorney:

Viksnins Harris Padys Malen LLP

Primary Examiner:

Brenda L Coleman

Int. Cl.
CPC ...
A61K 31/551 (2006.01); C07D 243/12 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); A61K 31/55 (2006.01); C07D 223/16 (2006.01); C07D 267/14 (2006.01); C07D 401/14 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 413/04 (2006.01); C07D 413/10 (2006.01); C07D 243/24 (2006.01); C07D 471/04 (2006.01); C07D 495/04 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); A61K 31/5513 (2006.01);
U.S. Cl.
CPC ...
A61K 31/55 (2013.01); A61K 31/337 (2013.01); A61K 31/5513 (2013.01); A61K 45/06 (2013.01); C07D 223/16 (2013.01); C07D 243/12 (2013.01); C07D 243/24 (2013.01); C07D 267/14 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 403/14 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 413/04 (2013.01); C07D 413/10 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01);
Abstract

The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Find Patent Forward Citations

Loading…